CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 22^nd Annual Needham Virtual Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.

Format: Virtual Presentation and 1x1 Investor Meetings
Virtual Presentation: April 19 from 12:45 - 1:25 pm ET in Track 1

The presentations will be webcast live and archived for 30 days in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

About Immuneering Corporation  

Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company’s development pipeline also includes IMM-6-415, a universal-MAPK program, as well as several early-stage programs. For more information, please visit www.immuneering.com.   

Media Contact:
Gina Nugent 
Nugent Communications 
617-460-3579 
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Contacts: 
Laurence Watts 
Gilmartin Group 
619-916-7620 
This email address is being protected from spambots. You need JavaScript enabled to view it.

or

Kiki Patel, PharmD 
Gilmartin Group 
332-895-3225
This email address is being protected from spambots. You need JavaScript enabled to view it.